Verified peer comparison

BMY vs MRK

Bristol-Myers Squibb Company compared with Merck & Co., Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

BMY

Bristol-Myers Squibb Company

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

MRK

Merck & Co., Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

BMY: Pharmaceuticals

MRK: Pharmaceuticals

Upside lens

BMY: Opdivo, Camzyos, Sotyktu, Breyanzi and Reblozyl can offset part of the mature-brand decline. Improved manufacturing and site expansion can increase patient throughput for Breyanzi and Abecma. Clinical and regulatory milestones can refresh the portfolio across oncology, immunology and neuroscience.

MRK: Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses. Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products. A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.

Risk lens

BMY: Generic and biosimilar competition can accelerate declines in major legacy products. Clinical setbacks or slow launches could leave growth products unable to replace lost legacy revenue. Acquisition-related debt can constrain flexibility while integration and milestone payments consume cash.

MRK: Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks. Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches. Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.

Verified sources

Bristol Myers Squibb Reports First Quarter 2026 Financial ResultsBristol-Myers Squibb Company · earningsVerified